Skip to main content
S&P 5007,711.06+1.88%DOW53,293.19+2.91%NASDAQ25,904.76+2.10%BTC$80,617.00+3.72%ETH$2,430.56+5.69%GOLD$4,076.60+3.46%OIL$88.12-8.29%
Smart Investors Daily
SID Premium
PH

NASDAQ · PHAT

Phathom Pharmaceuticals, Inc.

Healthcare · Biotechnology

$5.74

Up+$0.12 (+2.06%)

Updated Nov 4, 2026, 6:10 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.04B
P/E ratio
-3.89
Dividend yield
0.00%
52-week range
$5.02 – $18.31
Volume
2.17M
Avg. volume
1.06M

Price performance · PHAT

PHAT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

PHAT closed at $5.74 after 21 trading sessions, down 15.34% for the selected period.

Last close
$5.74
Period change
-15.34%
Period low
$5.74
Period high
$7.50
Daily close
View OHLC price history
PHAT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$5.92$6.11$5.50$5.742.17M
Nov 2, 2026$5.76$5.925$5.495$5.9152.81M
Oct 30, 2026$6.32$6.32$5.59$5.741.62M
Oct 29, 2026$7.00$7.00$5.71$6.223.84M
Oct 28, 2026$5.94$6.43$5.85$6.282.08M
Oct 27, 2026$5.91$6.18$5.81$5.992.1M
Oct 26, 2026$5.70$6.06$5.70$5.942.11M
Oct 23, 2026$6.72$6.76$5.015$5.744.87M
Oct 22, 2026$7.04$7.2173$6.965$7.01811.71K
Oct 21, 2026$7.31$7.48$7.01$7.03784.18K
Oct 20, 2026$7.04$7.40$6.96$7.31724.32K
Oct 19, 2026$6.88$7.05$6.78$7.011.02M
Oct 16, 2026$7.51$7.5699$6.90$6.921.25M
Oct 15, 2026$7.54$7.69$7.41$7.501.21M
Oct 14, 2026$6.97$7.72$6.9178$7.401.72M
Oct 13, 2026$7.14$7.16$6.86$7.001.95M
Oct 12, 2026$7.25$7.285$7.03$7.131.01M
Oct 9, 2026$7.13$7.30$7.015$7.25928.34K
Oct 8, 2026$6.79$7.18$6.68$7.131.33M
Oct 7, 2026$6.87$7.03$6.60$6.811.63M
Oct 6, 2026$6.75$6.80$6.52$6.782.09M

Latest PHAT news

The latest Smart Investors Daily articles mentioning PHAT.

Stock researchCompany · Overview

PHAT research

Overview

Company profile and research snapshot.

Company profile

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.40
Implied upside
—
Analysts
—
PHAT recent ratings
DateFirmRatingTarget
Sep 9, 2026Leerink PartnersMarket Perform—
Aug 17, 2026BarclaysOverweight—
Jul 31, 2026HC Wainwright & Co.Buy—
Jul 31, 2026GuggenheimBuy—
Jul 30, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 3, 2026

Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx

Potential to pay as little as $0 per fill for VOQUEZNA, plus free home delivery and prior authorization support, makes it simpler for GERD patients to get the medicine their doctor prescribed A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, today

Yahoo · Oct 29, 2026

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company continued efforts to expand access to its GERD treatment VOQUEZNA. Net revenue reached $84.7 million, up

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By